Xenitra Raises $1.25m to Fund OTC Expansion and Tokenisation Growth

AuMake Ltd. ( (AU:XEN) ) has shared an update.

Xenitra Limited has secured commitments from institutional, professional and sophisticated investors to raise $1.25 million via a share placement at $0.003 per share, with attaching options exercisable at $0.004 subject to shareholder approval. The deal, managed by Novus Capital, modestly dilutes existing holders but strengthens Xenitra’s balance sheet, providing capital to accelerate its OTC medicines expansion, scale its OPAL RWA token ecosystem across new brands, and fund working capital and infrastructure for the next phase of growth.

As part of the transaction, Xenitra will issue up to 416,666,667 new shares under its existing placement capacity, plus additional shares and options to Novus as lead manager, further increasing the company’s equity base. The capital injection underscores investor appetite for Xenitra’s dual focus on consumer health and tokenisation, positioning the company to pursue growth initiatives that could enhance market presence and potentially improve long-term shareholder value if execution is successful.

More about AuMake Ltd.

Xenitra Limited is an Australia-based company listed on the ASX, focused on over-the-counter medicines and developing the OPAL real-world asset token ecosystem. The business is oriented toward scaling health-related consumer products alongside blockchain-enabled tokenisation solutions for brands seeking new digital growth channels.

Current Market Cap: A$15.45M

See more insights into XEN stock on TipRanks’ Stock Analysis page.